Navigation Links
Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
Date:4/26/2013

MONROVIA, Calif., April 26, 2013 /PRNewswire/ -- Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 is a potent anti-CD19 monoclonal antibody Fc optimized for high cytotoxic function for which MorphoSys licensed exclusive worldwide rights from Xencor in 2010. The dosing of the first patient in the study triggers an undisclosed milestone payment to Xencor.

The US-based study is an open-label, multicenter, single-arm clinical trial designed to assess the efficacy of MOR208 in patients suffering from relapsed or refractory B-ALL. Secondary outcome measures include response duration, safety and pharmacokinetics of MOR208. In total, 30 patients are planned to be enrolled. More information on the trial can be found by searching for MOR208 at www.clinicaltrials.gov.

"Preclinical and early clinical studies of MOR208 have shown promising anti-tumor activity and supported this additional study in ALL as well as another study in Non Hodgkin's Lymphoma which is expected to start shortly," said Bassil Dahiyat , Ph.D., Chief Executive Officer of Xencor. "Xencor monoclonal antibody candidates continue to advance in clinical development and showcase the value of our XmAb® Fc technology."

MOR208 has shown in a Phase 1/2a trial encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In addition to the phase 2 trial in B-ALL MorphoSys is about to start a second Phase 2 trial in Non-Hodgkin's Lymphoma (NHL).

B-cell malignancies, such as B-ALL, NHL and CLL affect more than one hundred and fifty thousand patients in the seven major markets each year. The target molecule CD19
'/>"/>

SOURCE Xencor
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Clinical trial for rabies monoclonal antibody
2. New monoclonal antibody developed that can target proteins inside cancer cells
3. Dual action polyclonal antibody may offer more effective, safer protection against osteoporosis
4. Flu antibody’s one-handed grab may boost effort toward universal vaccine, new therapies
5. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
6. Labor der Zukunft -- Tomorrows laboratory technology
7. The future of plant science - a technology perspective
8. The future of plant science a technology perspective
9. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
10. UF researchers look for ways to make an emerging technology safe for environment
11. Breast cancer risk gene discovery fast tracked by new technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... According to a new market ... Type (Pen & Paper Based, Hosted, Biometrics), Service, Application ... Research), Vertical and Region - Global Forecast to 2020", ... grow from USD 2.4 Billion in 2015 to USD ... Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)... -- Based on its recent analysis of the biometric products market, ... Company of the Year Award. DERMALOG is the leading German ... Africa . It has particularly gained prominence in ... of the largest biometric mass applications in the world, and ... of Nigeria with its biometric products. ...
(Date:8/19/2015)... 2015  VOXX International Corporation (Nasdaq: VOXX ... a Definitive Agreement to purchase the assets, inclusive ... leader EyeLock through an acquiring entity.  Upon consummation ... interest in the acquiring entity. The closing of ... diligence.  Expanding on its existing supply chain and ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Fungi play key roles in nature and are valued for ... in several foods and pharmaceuticals produced on a large-scale basis for ... . While A. niger is an integral player in ... be deployed in breaking down plant cell walls to free up ...
... has a photo of a cornfield and a big photovoltaic ... Washington University in St. Louis. "When I give talks I ... the audience votes overwhelmingly in favor of photosynthesis. " ... (below) is the point of departure for a provocative article ...
... (May 3, 2011) Cancer studies from Mercer University ... the American Association of Pharmaceutical Scientists, (AAPS) National Biotechnology ... -Wednesday, May 18 at the Hilton San Francisco Union ... for Cervical Cancer Cervical cancer is the ...
Cached Biology News:Same fungus, different strains 2Same fungus, different strains 3Turning plants into power houses 2Turning plants into power houses 3Turning plants into power houses 4Turning plants into power houses 5Turning plants into power houses 6AAPS national biotechnology conference to highlight breakthrough cancer treatments 2
(Date:9/2/2015)... ARBOR, Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, analytical ... Avarent LLC, a consulting firm with expertise in medical device products/processes development, ...
(Date:9/2/2015)... Florida (PRWEB) , ... September 02, 2015 , ... ... been treated and managed with the use of special anti-vascular endothelial growth factor ... in many more patients, currently does not have a scientific protocol for the ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/bvxxkf/cytogenetics ) has announced the addition ... - Technologies, Markets and Companies" to ... cytogenetics includes several technologies besides fluorescence in ... and multicolor FISH. Molecular cytogenetics includes application ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... ever involving patients with cutaneous T-cell lymphoma on schedule ... RADNOR, Pa., June 29 Yaupon Therapeutics, a privately ... enrollment for a pivotal Phase 2 clinical trial for ... (CTCL - stages 1-2a). The study, which is ...
... DOR BioPharma, Inc. ... late-stage biopharmaceutical company, announced today that investigators at the ... paper this morning in Bone Marrow Transplantation ... (oral beclomethasone dipropionate or BDP) decreases non-infectious inflammation of ...
... 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... product development company that identifies and advances a ... stages of development, today reported that YM,s subsidiary, ... the issues between the companies in a cooperative ...
Cached Biology Technology:Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 2DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 3DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 4DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 5DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation 6YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 2YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 3YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 4
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
... latest entry in the Biomek line. With an,up-to-date ... robustness, it can meet the needs of just ... either one or two pipetting pods. With its ... standard for flexible laboratory solutions to meet your ...
... The Biomek FX P is the ... hardware design for greater positional accuracy and increased ... about any application. It can be configured with ... large deck capacity, the Biomek FX P ...
... and you reduce the chance of error. ... 8000. Developed using Beckman Coulters extensive experience ... electrophoresis technology, the CEQ 8000 is a ... automatically fills the capillary array with a ...
Biology Products: